Literature DB >> 6108713

Ulcerative colitis and its treatment.

A I Jacknowitz.   

Abstract

Ulcerative colitis and its epidemiology, etiology, pathophysiology, diagnosis, clinical findings, complications, treatment, and prognosis are reviewed. Ulcerative colitis, an inflammatory disease of unknown origin that varies in severity and clinical course, occurs most often in patients 30 to 70 years old. It appears to have a genetic component and to involve the immunological system. The cardinal symptom is usually bloody diarrhea, and the disease may be classified by either the severity of an attack, the clinical course, or by anatomic localization of inflammation. Initial treatment of ulcerative colitis generally includes corticosteroids administered either rectally, orally, or parenterally. Oral sulfasalazine has been found useful in treating this condition and is often used for prolonged therapy to prevent relapses. Azathioprine, cromolyn sodium, antidiarrheal/anticholinergic agents, and nutritional supplements are used at times. Surgery is indicated under certain conditions and usually involves panproctocolectomy with permanent ileostomy. The prognosis of ulcerative colitis depends upon the age of the patient, the extent of colonic involvement, and the severity of the attach.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108713

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  3 in total

1.  Indomethacin-induced intestinal ulcers in rats: effects of salicylazosulfapyridine and dexamethasone.

Authors:  P Del Soldato; D Foschi; L Varin; S Daniotti
Journal:  Agents Actions       Date:  1985-07

2.  Therapeutic effects of an azaphenothiazine derivative in mouse experimental colitis.

Authors:  Jolanta Artym; Maja Kocięba; Ewa Zaczyńska; Michał Zimecki; Wojciech Kałas; Leon Strządała; Alicja Pawlak; Małgorzata Jeleń; Beata Morak-Młodawska; Krystian Pluta; Katarzyna Kaleta-Kuratewicz; Jan P Madej; Piotr Kuropka; Jan Kuryszko
Journal:  Histol Histopathol       Date:  2019-12-13       Impact factor: 2.303

3.  Effects of miR-939 and miR-376A on ulcerative colitis using a decoy strategy to inhibit NF-κB and NFAT expression.

Authors:  Yongwei Lin; Zhipeng Zhou; Lang Xie; Yongsheng Huang; Zhenghua Qiu; Lili Ye; Chunhui Cui
Journal:  Eur J Histochem       Date:  2022-02-15       Impact factor: 3.188

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.